CELC Stock Price, Celcuity Inc Quote, Chart

Market Summary

USD17.24-0.30

Market Closed

-1.71%

CELC Stock Price

View Fullscreen

CELC RSI Chart

CELC Valuation

Market Cap

525.0M

Price/Earnings (Trailing)

-8.23

EV/EBITDA

-8.48

Price/Free Cashflow

-9.74

MarketCap/EBT

-8.23

CELC Price/Sales (Trailing)

CELC Profitability

Return on Equity

-45.63%

Return on Assets

-33.35%

Free Cashflow Yield

-10.27%

CELC Fundamentals

CELC Earnings

Earnings (TTM)

-63.8M

Earnings Growth (Yr)

-62.75%

Earnings Growth (Qtr)

-2.41%

Breaking Down CELC Revenue

Last 7 days

0.1%

Last 30 days

-3.0%

Last 90 days

19.4%

Trailing 12 Months

79.4%

How does CELC drawdown profile look like?

CELC Financial Health

Current Ratio

13.43

CELC Investor Care

Shares Dilution (1Y)

38.79%

Diluted EPS (TTM)

-2.82

Tracking the Latest Insider Buys and Sells of Celcuity Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	sullivan brian f.	gifted	-	-	765,897	chief executive officer
Mar 18, 2024	sullivan brian f.	gifted	-	-	-765,897	chief executive officer
Feb 21, 2024	buller richard e	sold	-4,952	14.15	-350	-
Jan 30, 2024	sullivan brian f.	gifted	-	-	-85,000	chief executive officer
Jan 30, 2024	sullivan brian f.	gifted	-	-	85,000	chief executive officer
Dec 27, 2023	sullivan brian f.	gifted	-	-	-1,733,350	chief executive officer
Dec 27, 2023	sullivan brian f.	gifted	-	-	863,347	chief executive officer
Dec 27, 2023	sullivan brian f.	gifted	-	-	870,000	chief executive officer
Dec 20, 2023	buller richard e	sold	-5,029	14.37	-350	-
Dec 15, 2023	dalvey david	sold	-42,847	14.5739	-2,940	-

Which funds bought or sold CELC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	49,815	133,665	-%
Apr 19, 2024	TRUST POINT INC.	reduced	-4.9	121,776	418,932	0.03%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	added	2.99	152,267	441,292	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Apr 05, 2024	GAMMA Investing LLC	unchanged	-	643	2,138	-%
Mar 11, 2024	VANGUARD GROUP INC	added	3.69	4,723,530	11,958,700	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	95.17	271,753	400,472	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	46,769	126,351	-%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	new	-	21,582,500	21,582,500	0.48%
Feb 15, 2024	PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.	unchanged	-	325,800	874,200	0.05%

Are Funds Buying or Selling CELC?

Are funds buying CELC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CELC

No. of Funds

Unveiling Celcuity Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	commodore capital lp	9.9%	2,492,886	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	9.99%	2,476,980	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	5.0%	1,286,960	SC 13G/A
Feb 14, 2024	perceptive advisors llc	6.1%	1,481,300	SC 13G/A
Feb 12, 2024	morgan stanley	9.1%	2,195,026	SC 13G/A
Feb 09, 2024	soleus capital master fund, l.p.	9.9%	2,623,890	SC 13G/A
Feb 07, 2024	laing lance g.	5.5%	1,421,036	SC 13G/A
Feb 07, 2024	sullivan brian f.	14.0%	3,648,665	SC 13G/A
Dec 26, 2023	perceptive advisors llc	5.7%	1,441,300	SC 13G
Feb 14, 2023	commodore capital lp	9.9%	2,257,412	SC 13G/A

Recent SEC filings of Celcuity Inc

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	4	Insider Trading
Mar 29, 2024	8-K	Current Report
Mar 29, 2024	ARS	ARS
Mar 28, 2024	DEF 14A	DEF 14A
Mar 28, 2024	DEFA14A	DEFA14A
Mar 27, 2024	10-K	Annual Report
Mar 27, 2024	8-K	Current Report
Mar 20, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 15, 2024	4	Insider Trading

Peers (Alternatives to Celcuity Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Celcuity Inc News

Latest updates

Celcuity Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	34.3%	191	142	154	165	176	65.00	72.00	80.00	86.00	92.00	43.00	36.00	13.00	15.00	17.00	18.00	20.00	22.00	23.00	25.00	26.00
Current Assets	34.5%	191	142	153	164	175	65.00	72.00	79.00	85.00	91.00	42.00	36.00	12.00	14.00	16.00	17.00	19.00	21.00	22.00	24.00	25.00
Cash Equivalents	19.0%	31.00	26.00	32.00	34.00	25.00	57.00	67.00	78.00	84.00	90.00	42.00	35.00	12.00	14.00	15.00	17.00	19.00	16.00	15.00	15.00	16.00
Net PPE	2.4%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	4.0%	51.00	49.00	43.00	42.00	42.00	22.00	19.00	18.00	17.00	17.00	16.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Current Liabilities	11.6%	14.00	13.00	7.00	6.00	7.00	7.00	4.00	4.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Shareholder's Equity	50.5%	140	93.00	110	123	134	44.00	53.00	62.00	69.00	74.00	27.00	35.00	12.00	14.00	16.00	18.00	19.00	21.00	22.00	24.00	25.00
Retained Earnings	-13.3%	-160	-141	-122	-108	-96.30	-84.72	-73.82	-63.86	-55.93	-49.17	-43.15	-29.11	-26.32	-23.77	-21.30	-19.09	-16.85	-15.04	-13.05	-11.33	-9.49
Additional Paid-In Capital	28.1%	300	234	233	231	230	128	127	125	125	124	70.00	64.00	38.00	38.00	37.00	37.00	36.00	36.00	35.00	35.00	35.00
Shares Outstanding	14.0%	26.00	22.00	22.00	22.00	22.00	15.00	15.00	15.00	15.00	13.00	12.00	11.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	191	-	-	-	96.00	-	-	-	198	-	-	-	41.00	-	-	-	146	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-45.4%	-18,535	-12,746	-9,662	-12,867	-9,479	-9,306	-11,289	-5,933	-6,124	-4,048	-7,617	-2,521	-2,107	-1,648	-1,556	-1,833	-1,703	-1,478	-1,226	-1,590	-1,519
Share Based Compensation	12.1%	1,243	1,109	1,277	1,273	1,139	1,223	1,519	756	921	700	540	449	427	449	423	465	361	303	192	185	256
Cashflow From Investing	-759.2%	-41,218	6,252	8,090	21,868	-143,985	-12.10	-22.99	-11.63	-9.94	-14.06	-26.97	-30.42	-13.88	-8.90	-20.98	-45.60	4,137	2,831	1,364	197	13,666
Cashflow From Financing	424046.8%	64,657	15.00	172	68.00	120,552	-108	-72.52	-46.29	54.00	52,791	14,346	25,851	63.00	-76.47	153	-1.44	32.00	-1.43	57.00	172	-10.76

CELC Income Statement

2023-12-31

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 60,594,005	$ 35,289,548
General and administrative	5,636,326	4,101,543
Total operating expenses	66,230,331	39,391,091
Loss from operations	(66,230,331)	(39,391,091)
Other income (expense)
Interest expense	(5,326,387)	(2,106,111)
Interest income	7,777,602	1,127,162
Other income (expense), net	2,451,215	(978,949)
Net loss before income taxes	(63,779,116)	(40,370,040)
Income tax benefits
Net loss	$ (63,779,116)	$ (40,370,040)
Net loss per share, basic	$ (2.69)	$ (2.64)
Net loss per share, diluted	$ (2.69)	$ (2.64)
Weighted average common shares outstanding, basic	23,679,472	15,418,543
Weighted average common shares outstanding, diluted	23,679,472	15,418,543

CELC Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 30,662,774	$ 24,571,557
Investments	149,919,974	144,015,954
Other current assets	10,007,849	6,603,026
Total current assets	190,590,597	175,190,537
Property and equipment, net	228,782	260,294
Operating lease right-of-use assets	400,019	246,266
Total Assets	191,219,398	175,697,097
Current Liabilities:
Accounts payable	5,076,699	2,627,076
Finance lease liabilities		2,449
Operating lease liabilities	184,950	191,749
Accrued expenses	8,927,094	4,060,280
Total current liabilities	14,188,743	6,881,554
Operating lease liabilities	225,922	61,002
Note payable, non-current	37,035,411	34,983,074
Total Liabilities	51,450,076	41,925,630
Commitments and Contingencies (Note 9)
Stockholders’ Equity:
Preferred stock, $0.001 par value: 2,500,000 shares authorized; 854,134 and 1,120,873 shares issued and outstanding as of December 31, 2023 and 2022, respectively	854	1,121
Common stock, $0.001 par value: 65,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 25,506,012 and 21,667,250 shares issued and outstanding as of December 31, 2023 and 2022, respectively	25,506	21,667
Additional paid-in capital	299,818,965	230,045,566
Accumulated deficit	(160,076,003)	(96,296,887)
Total Stockholders’ Equity	139,769,322	133,771,467
Total Liabilities and Stockholders’ Equity	$ 191,219,398	$ 175,697,097

About Celcuity Inc

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

CEO	Mr. Brian F. Sullivan
WEBSITE	celcuity.com
INDUSTRY	Biotechnology
EMPLOYEES	45

Celcuity Inc Frequently Asked Questions

What is the ticker symbol for Celcuity Inc? What does CELC stand for in stocks?

CELC is the stock ticker symbol of Celcuity Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Celcuity Inc (CELC)?

As of Tue Apr 23 2024, market cap of Celcuity Inc is 525.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CELC stock?

You can check CELC's fair value in chart for subscribers.

What is the fair value of CELC stock?

You can check CELC's fair value in chart for subscribers. The fair value of Celcuity Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Celcuity Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CELC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Celcuity Inc a good stock to buy?

The fair value guage provides a quick view whether CELC is over valued or under valued. Whether Celcuity Inc is cheap or expensive depends on the assumptions which impact Celcuity Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CELC.